Belite Bio (BLTE) Competitors $66.27 +0.59 (+0.90%) Closing price 04:00 PM EasternExtended Trading$64.15 -2.12 (-3.20%) As of 04:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BLTE vs. RVMD, GRFS, RYTM, LEGN, ABVX, AXSM, RNA, NUVL, MRUS, and CRSPShould you be buying Belite Bio stock or one of its competitors? The main competitors of Belite Bio include Revolution Medicines (RVMD), Grifols (GRFS), Rhythm Pharmaceuticals (RYTM), Legend Biotech (LEGN), Abivax (ABVX), Axsome Therapeutics (AXSM), Avidity Biosciences (RNA), Nuvalent (NUVL), Merus (MRUS), and CRISPR Therapeutics (CRSP). These companies are all part of the "pharmaceutical products" industry. Belite Bio vs. Its Competitors Revolution Medicines Grifols Rhythm Pharmaceuticals Legend Biotech Abivax Axsome Therapeutics Avidity Biosciences Nuvalent Merus CRISPR Therapeutics Belite Bio (NASDAQ:BLTE) and Revolution Medicines (NASDAQ:RVMD) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership. Do analysts prefer BLTE or RVMD? Belite Bio currently has a consensus price target of $96.67, indicating a potential upside of 45.87%. Revolution Medicines has a consensus price target of $72.00, indicating a potential upside of 78.00%. Given Revolution Medicines' higher possible upside, analysts clearly believe Revolution Medicines is more favorable than Belite Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Belite Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Revolution Medicines 0 Sell rating(s) 0 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is BLTE or RVMD more profitable? Belite Bio's return on equity of -34.90% beat Revolution Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Belite BioN/A -34.90% -33.56% Revolution Medicines N/A -41.78%-35.63% Which has more volatility and risk, BLTE or RVMD? Belite Bio has a beta of -1.5, meaning that its share price is 250% less volatile than the S&P 500. Comparatively, Revolution Medicines has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Do institutionals and insiders have more ownership in BLTE or RVMD? 0.5% of Belite Bio shares are owned by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by insiders. Comparatively, 8.2% of Revolution Medicines shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has preferable earnings & valuation, BLTE or RVMD? Belite Bio has higher earnings, but lower revenue than Revolution Medicines. Belite Bio is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBelite BioN/AN/A-$36.14M-$1.55-42.75Revolution Medicines$11.58M652.96-$600.09M-$4.50-8.99 Does the media favor BLTE or RVMD? In the previous week, Revolution Medicines had 16 more articles in the media than Belite Bio. MarketBeat recorded 21 mentions for Revolution Medicines and 5 mentions for Belite Bio. Revolution Medicines' average media sentiment score of 0.87 beat Belite Bio's score of 0.84 indicating that Revolution Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Revolution Medicines 11 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryRevolution Medicines beats Belite Bio on 8 of the 13 factors compared between the two stocks. Get Belite Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for BLTE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BLTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BLTE vs. The Competition Export to ExcelMetricBelite BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.09B$3.18B$5.83B$10.07BDividend YieldN/A2.26%5.25%4.53%P/E Ratio-42.7521.3175.5726.01Price / SalesN/A453.06536.77117.75Price / CashN/A45.8737.4259.95Price / Book14.049.6011.536.20Net Income-$36.14M-$53.33M$3.29B$270.65M7 Day Performance4.35%0.61%0.44%2.77%1 Month Performance-5.17%11.11%10.84%8.83%1 Year Performance35.52%12.61%61.62%27.49% Belite Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BLTEBelite Bio2.3065 of 5 stars$66.27+0.9%$96.67+45.9%+34.4%$2.09BN/A-42.7510News CoverageRVMDRevolution Medicines4.2596 of 5 stars$37.97-0.9%$69.92+84.2%-2.8%$7.10B$11.58M-8.44250GRFSGrifols4.1753 of 5 stars$9.97+1.0%$10.30+3.3%+15.3%$6.85B$7.81B8.5223,822News CoveragePositive NewsRYTMRhythm Pharmaceuticals3.1119 of 5 stars$103.15-1.0%$101.57-1.5%+100.2%$6.85B$130.13M-34.27140Positive NewsLEGNLegend Biotech3.4446 of 5 stars$34.73+1.0%$74.22+113.7%-32.0%$6.41B$627.24M-39.472,609Positive NewsABVXAbivax2.6539 of 5 stars$81.03-0.7%$92.33+13.9%+643.8%$6.12BN/A0.0061News CoverageEarnings ReportAnalyst ForecastAXSMAxsome Therapeutics4.7456 of 5 stars$121.28-0.4%$178.00+46.8%+33.6%$6.05B$385.69M-23.92380Positive NewsInsider TradeRNAAvidity Biosciences2.3829 of 5 stars$46.58-4.1%$67.00+43.8%+14.4%$5.99B$10.90M-13.08190Trending NewsAnalyst ForecastInsider TradeNUVLNuvalent2.6915 of 5 stars$76.58+0.7%$120.80+57.7%-11.8%$5.52BN/A-15.6340Analyst ForecastMRUSMerus3.1512 of 5 stars$65.84-0.4%$88.75+34.8%+36.7%$4.98B$36.13M-11.9737Positive NewsCRSPCRISPR Therapeutics3.0074 of 5 stars$51.83-2.3%$71.60+38.1%+19.7%$4.71B$37.31M-9.55460Positive News Related Companies and Tools Related Companies RVMD Alternatives GRFS Alternatives RYTM Alternatives LEGN Alternatives ABVX Alternatives AXSM Alternatives RNA Alternatives NUVL Alternatives MRUS Alternatives CRSP Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BLTE) was last updated on 9/10/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredWall Street Legend Names #1 ‘Hidden’ AI Stock50-year Wall Street legend says to forget NVDA. For the biggest potential gains, it's time to move your money ...Chaikin Analytics | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Belite Bio, Inc. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Belite Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BLTE Stock Alerts